ICU — SeaStar Medical Holding Corporation

SeaStar Medical Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics:

• Net Revenue: Reported net revenue of approximately $183,000 for Q3 2025, a significant increase from $68,000 in Q3 2024.
• Gross Profit Margin: Achieved a gross profit margin of 92% for the quarter, reflecting the first full quarter of cost of goods sold for Quellimmune.
• Operating Expenses: Decreased to $3.7 million from $4.5 million year-over-year, primarily due to reduced consulting and personnel costs.
• Net Loss: Reported a net loss of approximately $3.5 million, or $0.13 per share, compared to a net loss of $4.5 million, or $1.10 per share, in the prior year.
• Cash Position: Ended the quarter with $13.8 million in cash, up from $1.8 million at the end of December 2024, bolstered by $12.4 million raised through equity offerings and warrant exercises.

2. Strategic Updates and Business Highlights:

• Customer Base Expansion: Added three top-ranked children's medical centers, bringing the total to 10 active commercial pediatric hospitals.
• Clinical Data Presentation: Reported impressive survival results from the SAVE surveillance registry for Quell immune therapy in 21 pediatric patients, with 76% survival at 60 days and 71% at 90 days.
• Clinical Trials: Completed an interim analysis for the neutralized AKI pivotal trial, which showed safety with no device-related adverse events. The sample size was increased from 200 to 339 patients to ensure adequate statistical power.
• New Trial Launch: Announced the initiation of a new trial for the SCD therapy in patients with cardiorenal syndrome, aiming to enroll 20 patients.

3. Forward Guidance and Outlook:

• Revenue Expectations: Anticipating full-year revenue for 2025 to exceed $1 million, with early Q4 orders already surpassing Q3 sales.
• Market Potential: Targeting a sizable portion of a $100 million U.S. market for Quellimmune therapy, with plans to expand into more pediatric hospital systems in 2026.
• Enrollment Goals: Committed to completing enrollment for the neutralized AKI trial by December 2026, with ongoing efforts to activate additional clinical sites.

4. Bad News, Challenges, or Points of Concern:

• Enrollment Challenges: The requirement for a registry has slowed site additions, impacting the speed of patient enrollment in clinical trials.
• Statistical Significance: The interim analysis indicated that the originally assumed effect size was not observed, leading to an increase in the sample size for the trial, which could delay results.
• Revenue Variability: Sales have been described as variable and lumpy, which may pose challenges in forecasting and financial stability.

5. Notable Q&A Insights:

• Enrollment Update: As of the call, 146 patients were enrolled in the neutralized AKI trial with 17 sites activated, with plans to increase to 25 sites.
• New Cardiorenal Trial: The new trial for cardiorenal syndrome is in early stages, with expectations to enroll 20 patients over the next year.
• Revenue Confirmation: Confirmed expectations for revenue exceeding $1 million for the full year 2025, addressing concerns about revenue volatility.

Overall, SeaStar Medical is making progress in expanding its customer base and clinical trials, while also managing financial losses and navigating challenges in patient enrollment and revenue variability.